Retatrutide 20mg

Retatrutide (development code LY3437943) is a synthetic 39-amino-acid peptide engineered to activate three metabolic receptors simultaneously: GLP-1, GIP, and glucagon (GCGR). It is the first triple agonist in the incretin class to publish Phase 2 data in both obesity and type 2 diabetes, and it has become the reference compound for researchers investigating multi-receptor metabolic signaling.

The design logic is deliberate. GLP-1 drives appetite suppression and glucose-dependent insulin release. GIP adds insulin sensitivity and fat metabolism. Glucagon—the receptor that distinguishes Retatrutide from dual agonists like tirzepatide—contributes energy expenditure and hepatic lipid oxidation, countering the metabolic slowdown that typically accompanies weight loss. The result, in preclinical and early clinical models, is a more aggressive metabolic effect than GLP-1 or GLP-1/GIP agonism alone.

This research-grade Retatrutide is supplied as a sterile, lyophilized powder, independently verified by HPLC-UV (≥98% purity) and LC-MS identity confirmation, with a batch-specific Certificate of Analysis for full traceability.

Proposed mechanisms of interest in published literature:

Triple receptor agonism (GLP-1R / GIPR / GCGR): Retatrutide binds all three incretin receptors, with comparatively higher activity at the human GIP receptor and lower potency at GCGR and GLP-1R relative to the native hormones. This receptor balance is central to its research profile.

Appetite suppression + energy expenditure: GLP-1 and GIP components reduce food intake and improve glycemic control, while glucagon receptor activation is studied for maintaining or increasing energy expenditure during weight loss—an effect observed in obese mouse models treated with Retatrutide.

Hepatic lipid reduction: In a nested MASLD substudy of the Phase 2 obesity trial, Retatrutide reduced liver fat by 42.9% to 82.4% at 24 weeks, with 86% of participants at the 12 mg dose achieving liver fat normalization.

Thermogenic signaling (preclinical): Glucagon receptor agonism has been reported to stimulate thermogenesis in brown and white adipose tissue through UCP1-dependent and FGF21-dependent pathways in preclinical models.

Extended pharmacokinetics: A C-20 fatty diacid modification promotes reversible binding to serum albumin, extending the half-life to approximately 6 days and supporting once-weekly dosing in clinical research settings.

Clinical research context (Phase 2 data):

Retatrutide has the most mature clinical dataset in the triple agonist class, though it remains investigational.

Obesity (48 weeks, n=338): Dose-dependent weight reduction ranging from −8.7% to −24.2%, versus −2.1% with placebo. Reductions of ≥20% were more common at doses of ≥4 mg.

Type 2 diabetes (36 weeks, n=281): Weight loss up to −16.3% (12 mg) versus +3.0% with placebo, alongside HbA1c reductions up to −2.16%. In the 12 mg arm, 93% of participants reached HbA1c ≤7.0%.

Body composition substudy (T2D): Total fat mass reduction reached 26.1% at the 8 mg dose by week 36.

Tolerability: Gastrointestinal events (nausea, diarrhea, vomiting) were the most common adverse effects, dose-dependent, with discontinuation rates of 6–16% in the Phase 2 program.

A comprehensive Phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes.

Product specifications:

Compound: Retatrutide (LY3437943)

CAS Number: 2381089-83-2 (free base)

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈ (free base); acetate salt forms available

Molecular Weight: 4731.34 g/mol (free base); ~4791.38 g/mol (acetate form)

Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-[diacid-C20-γ-Glu-(AEEA)-Lys]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Peptide Length: 39 amino acids, with non-coded residues (Aib at positions 2 and 20; α-methyl-leucine at position 13) and a C-terminal amide

Appearance: White to off-white powder

Form: Lyophilized powder

Purity: ≥98% by HPLC-UV (batch-specific COA; representative research lots test 99.0%–99.8%)

Identity Confirmation: LC-MS (mass spectrometry)

Solubility: Soluble in bacteriostatic water and sterile saline

Storage (lyophilized): −20°C, desiccated, protected from light

Handling & reconstitution (research context):

Reconstitute with bacteriostatic water using aseptic technique. Inject the water slowly down the inner glass wall of the vial—do not spray directly onto the powder—then gently swirl or roll the vial. Do not shake or vortex; the 39-amino-acid sequence and its lipid modification are sensitive to aggressive agitation.

Once reconstituted, store refrigerated at 2–8°C and use within 2–4 weeks. Do not freeze reconstituted peptide. Aliquot into single-use volumes where protocol permits to avoid repeated freeze–thaw cycles.

Quick answers

Who should be buying the 20mg strength?

Mid-protocol users: the vial sized for holding the 3-4mg weekly band for a full month without reconstitution math every week. If you have survived 10mg without your diet collapsing, this is the cruising strength where results compound. Anyone still at week two of a ladder has no business here yet - tolerance earns the jump, not impatience.

Does hunger suppression get dangerous at this dose?

It gets real: protein-first meals become non-negotiable or the scale eats muscle instead of fat. Structure intake, keep lifting, and step up only when side effects have flattened out for two straight weeks.

What if sides hit hard on the jump?

Hold at the current step an extra two weeks instead of retreating - most nausea is new-step nausea, not permanent. Hydration, smaller plates, fat last at meals; full protocol notes on the fat burners shelf.